CIAM
NPCE icon

Caitong International Asset Management’s Neuropace NPCE Stock Holding History

Caitong International Asset Management’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$48 Buy
+3
New +$48 ﹤0.01% 2352

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Caitong International Asset Management's NPCE Position: Q2 2026 in Review

Caitong International Asset Management opened a new position in Neuropace (NPCE) in Q2 2026: 3 shares worth $48. The stake represents ﹤0.01% of the portfolio and ranks #2352 among its holdings.

113 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.

  • Caitong International Asset Management held 3 shares of Neuropace worth $48 as of Q2 2026.
  • Neuropace was a new Caitong International Asset Management position in Q2 2026.
  • Neuropace made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #2352 holding.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.